The biotech continues to earn important wins, but is it enough?Vaccine maker Novavax (NVAX -3.01%) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (SNY -1.24%), sending its stock price soaring. Novavax has made quite a comeback for a company that raised doubts about its ability to stay in business just 18 months ago. But Novavax isn't done. The biotech just announced a regulatory win that has some investors excited. Let's find out whether Novavax ...